Cargando…

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

Advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) have led to improved progression-free survival of many patients; however the therapies are toxic, rarely achieve durable long-term complete responses and are not curative. Herein we used a single bicistronic lentiviral v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suarez, Eloah Rabello, Chang, De-Kuan, Sun, Jiusong, Sui, Jianhua, Freeman, Gordon J., Signoretti, Sabina, Zhu, Quan, Marasco, Wayne A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085160/ https://www.ncbi.nlm.nih.gov/pubmed/27145284 http://dx.doi.org/10.18632/oncotarget.9114

Ejemplares similares

Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo
por: Chang, De-Kuan, et al.
Publicado: (2015)

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022)

Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor
por: Lo, Agnes Shuk-Yee, et al.
Publicado: (2014)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

The growth and potential of human antiviral monoclonal antibody therapeutics
por: Marasco, Wayne A, et al.
Publicado: (2007)

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
por: Chang, De-Kuan, et al.
Publicado: (2015)

Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma
por: Han, Thomas, et al.
Publicado: (2012)

Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma
por: Hill, Brian T., et al.
Publicado: (2019)

Heparan sulfate mediates trastuzumab effect in breast cancer cells
por: Suarez, Eloah Rabello, et al.
Publicado: (2013)

CAR-T cells: Early successes in blood cancer and challenges in solid tumors
por: Dana, Hassan, et al.
Publicado: (2021)

Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model
por: Wang, Yufei, et al.
Publicado: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Shen, Chunyi, et al.
Publicado: (2021)

Epitope-based vaccines: SARS – a model
por: Freund, Natalia Tarnovitski, et al.
Publicado: (2006)

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
por: Qin, Le, et al.
Publicado: (2020)

Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain
por: Zhang, Ang, et al.
Publicado: (2023)

Studies in CRISPR-generated Mediterranean G6PD variant rats reveal G6PD orchestrates genome-wide DNA methylation and gene expression in vascular wall
por: Signoretti, Christina, et al.
Publicado: (2023)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
por: Tang, Xin, et al.
Publicado: (2021)

Lentivirus Display: Stable Expression of Human Antibodies on the Surface of Human Cells and Virus Particles
por: Taube, Ran, et al.
Publicado: (2008)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve
por: Fu, Ying, et al.
Publicado: (2016)

Mapping a Neutralizing Epitope on the SARS Coronavirus Spike Protein: Computational Prediction Based on Affinity-selected Peptides
por: Tarnovitski, Natalia, et al.
Publicado: (2006)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
por: Yang, Ching-Yao, et al.
Publicado: (2020)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
por: Nellan, Anandani, et al.
Publicado: (2018)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells
por: Fang, Yuan, et al.
Publicado: (2020)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
por: Grassmann, S, et al.
Publicado: (2014)

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
por: Liao, Qibin, et al.
Publicado: (2020)

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
por: Liu, Wai Nam, et al.
Publicado: (2022)

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
por: Guo, Xingliang, et al.
Publicado: (2018)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
por: Zhao, Jingjing, et al.
Publicado: (2023)

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients
por: Zhou, Yuxin, et al.
Publicado: (2023)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hgbagcpnb8q0iujn8a2v7cgfo4